Natco Pharma Ltd has received final approval from the USFDA to market Bosentan 32mg tablets. This drug, Bosentan 32mg tablets is used for the treatment of pulmonary arterial hypertension (PAH).

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Competition page helps you compare Natco Pharma Ltd. with its sector peers on key parameters.

Natco Pharma Ltd., incorporated in the year 1981, is a Mid Cap company (having a market cap of Rs 22,961.89 Crore) operating in Pharmaceuticals sector. Natco Pharma Ltd. key Products/Revenue Segments ...

Tata Equity P/E Fund - (G) 195.45 16,65,000 2.42 Tata Equity P/E Fund-(IDCW-Trigger-Opt B-10%) 195.45 16,65,000 2.42 Tata Equity P/E Fund - (IDCW-Trigger - Opt A - 5% ...

Natco Pharma has received U.S. Food and Drug Administration final approval for Bosentan tablets for oral suspension, 32mg, its generic version of Actelion Pharmaceuticals US Inc.’s pulmonary ...

Hyderabad: Global pharma major Lupin Limited (Lupin) and its alliance partner Natco Pharma Limited (Natco) have announced that they received the approval from the United States Food and Drug ...

Natco Pharma Ltd. is a Public Limited Listed company incorporated on 19/09/1981 and has its registered office in the State of Telangana, India. Company's Corporate Identification Number(CIN) is ...

The pharmaceutical firm’s consolidated revenue from operations fell to ₹474.8 crore in Q3 FY2025, down from ₹758.6 crore in the year-ago period, reflecting a 37.4 percent decrease in earnings.

Drug maker Natco Pharma on Monday, February 10, announced securing the final approval from the United States Food and Drug Administration (USFDA) for its Bosentan tablets, which are used in treating ...

Natco Pharma is engaged in the business of pharmaceuticals which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The company has ...